Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation, page-15

I raised this issue at yesterday's investor lunch. Need some positive promotion badly in between updates that are dictated mostly by clinical progress.

Seems management is letting it drift. They have said previously that there is a gap in our valuation and the value of the underlying assets and I 100% agree. What is management doing to better inform the market in order to close this preceived gap? This gap needs to be closed before the next cap raise and CHM cannot leave it to market updates like CDH17 first dosing etc as we know there is potenetial here but the lead time is an issue with the pending funding requirements of the business in the meantime.

CHM needs to spruik the value of the tech and get some positive retail momentum and uplift in the SP before they go to the Soph's and Instituitions for funding.

I will post some feedback from yesterday when I get some time.